Stocks are down to start the week, but Eli Lilly's and Johnson & Johnson's drugs are rising on new data.
The AI component trade is surging, while software stocks are under pressure.
Eli Lilly's Foundayo weight-loss drug is starting to compete with Novo Nordisk's Wegovy.
According to the latest report, Foundayo's prescriptions have increased by 14%.
Johnson & Johnson's Icotyde, which is approved for treating skin conditions, is also starting to gain traction.
These developments come as interest rates continue to creep higher.
